Business news

    MGC Pharmaceuticals (ASX:MXC) enrols first patient in medicinal cannabis trial

    Article Image

    MGC Pharmaceuticals (ASX:MXC) has enrolled the first patient in the company's proprietary data collection App and machine learning algorithm, ZAM, to monitor the effects of MGC Pharma's epilepsy treatment, CannEpil™.

    The App will provide medical practitioners and MGC Pharma with a detailed record of the study and an enhanced understanding of the effect of CannEpil™ on Refractory Epilepsy patients.

    MGC Pharma says the trial is supported by the “I am Billy” Foundation, a charity set up to aid parents and families in obtaining NHS-funded Medical Cannabis.

    MGC Pharma has partnered with renowned institutions and academia to optimise the development of targeted plant inspired medicines, and has a global distribution footprint via an extensive network of commercial partners to supply the global market.

     

    Disclaimer

    Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relates to your unique circumstances. Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of, or reliance on the information provided directly or indirectly by use of this platform.

    Publisher
    Grafa